Zim Laboratories enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023


756	—	—	—	—
25.1	25.1	1.9	9.6	6.4
0.0	0.0	0.0	0.0	0.0
123	123	112	106	59.6
854	—	—	—	—
97.9	97.9	110	96.8	53.1
₹159.55	—	—	—	—

419	419	364	345	260
29.3%	29.3%	30.8%	30.8%	22.9%
0.14×	—	—	—	—

2.15×	—	—	—	—
30.27×	—	—	—	—
110.64×	—	—	—	—
165.83×	—	—	—	—
397	374	379	367	399
28.2	30.0	43.7	41.3	52.0
7.7	10.0	23.6	25.4	34.5
—	49.5	41.2	16.3	37.5
5.1	5.1	0.4	−57.6	0.9
—	1.4	−3.6	−59.7	−0.9
—	44.4	40.8	73.9	36.7

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZIMLAB₹141.26

Zim Laboratories Limited

· Pharma & Health

₹ CrorePeersANUHPHR VALIANTLAB AHCL ALBERTDAVD WANBURY HALEOSLABS BAJAJHCARE THEMISMEDMcap ₹756 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	755.7
- Cash, Equiv & ST Investments	6.4	9.6	1.9	25.1	25.1
+ Minority Interest	0.0	0.0	0.0	0.0	0.0
+ Total Debt	59.6	106.4	112.2	123.0	123.0
Enterprise Value	—	—	—	—	853.6
Net Debt (memo)	53.1	96.8	110.2	97.9	97.9
EV per Share	—	—	—	—	159.55

Total Capital	259.9	345.1	364.4	419.1	419.1
Total Debt/Total Capital	22.92	30.82	30.78	29.34	29.34
Total Debt/EV	—	—	—	—	0.14

EV/Sales	—	—	—	—	2.15
EV/EBITDA	—	—	—	—	30.27
EV/EBIT	—	—	—	—	110.64
EV/Free Cash Flow	—	—	—	—	165.83
Reference Items — Trailing FY Values
Sales	398.5	367.4	379.0	374.4	396.8
EBITDA	52.0	41.3	43.7	30.0	28.2
EBIT	34.5	25.4	23.6	10.0	7.7
Operating Cash Flow	37.5	16.3	41.2	49.5	—
Free Cash Flow	0.9	-57.6	0.4	5.1	5.1
FCFF (free cash flow to the firm)	-0.9	-59.7	-3.6	1.4	—
Capital Expenditure	36.7	73.9	40.8	44.4	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.